The JAK/STAT3-targeted tyrosine kinase inhibitor (e.g. sunitinib) may nevertheless be considered an interesting strategy in the therapy of infiltrative BIA-ALCL. This evidence concerns the gene STAT3 and anaplastic large cell lymphoma.